Skip to content

Analgesic Effect of rTMS in Vasculitic Neuropathy

Analgesic Effect of Repetitive Transcranial Magnetic Stimulation in Painful Vasculitic Neuropathy

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04720196
Enrollment
3
Registered
2021-01-22
Start date
2021-01-25
Completion date
2023-09-21
Last updated
2023-10-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vasculitic Neuropathy

Keywords

vasculitis, neuropathy, pain, transcranial magnetic stimulation, analgesic effect

Brief summary

Vasculitic neuropathy (VN) results from inflammation and destruction of the walls of predominantly small vessels with subsequent ischemic damage of peripheral nerves. VN is painful in vast majority of patients and the pain is intractable with pharmacotherapy in about 40% of cases. Repetitive Transcranial Magnetic Stimulation (rTMS) is a noninvasive method of modulation of brain plasticity and is regarded as one of alternative methods to alleviate pain associated with various kind of neuropathies. The purpose of this study is to compare the effectiveness of analgesic effect of rTMS in vasculitic neuropathy with sham stimulation.

Detailed description

Vasculitic neuropathies (VN) are a group of disorders resulting from inflammation of predominantly small vessels with destruction of their walls and subsequent ischemic damage of peripheral nerves. Neural damage may or may not coexist with the damage of other organs. Examples of conditions associated with VN include diabetes, microscopic polyangiitis, eosinophilic granulomatosis with polyangiitis (Churg-Strauss), granulomatosis with polyangiitis (Wegener's), rheumatoid arthritis, systemic lupus erythematosus and others. VN is painful in about 80% of patients of whom 40% suffer from the pain intractable with pharmacological therapy. Repetitive Transcranial Magnetic Stimulation (rTMS) is a noninvasive method of modulation of brain plasticity. In this method, series of magnetic stimuli are delivered to the cerebral cortex, where they turn to electric current and depolarize repetitively the targeted neurons. If the stimulation is repeated during subsequent days it is capable to modify the activity of targeted cortical area for weeks or even months and by this way to achieve therapeutic effect. rTMS is widely regarded as one of alternative methods to alleviate pain associated with various kind of neuropathies. The purpose of this study is to compare the effectiveness of analgesic effect of rTMS in vasculitic neuropathy with sham stimulation.

Interventions

High frequency rTMS over the primary motor area to induce the long term potentiation of primary motor areas for the muscles of upper extremity.

DEVICESham repetitive transcranial magnetic stimulation

Sham stimulation to mimic the high frequency rTMS over the primary motor area.

Sponsors

Jagiellonian University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Masking description

Sham stimulation will be provided by holding the stimulating coil perpendicularly to the scalp, which assures similar impression as during active stimulation but prevents significant magnetic field to reach the brain tissue.

Intervention model description

Patients will be randomly assigned to active and then sham stimulation or to sham and then active stimulation.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Diagnosis of vasculitic neuropathy * Neuropathic pain of constant severity since not less than a month and requiring use of analgesics more than once a week * Score of 30 milimeter or more on the 100 milimeter visual analog scale of pain intensity at inclusion

Exclusion criteria

* Severe depression * Personality disorders and other psychiatric conditions, which could disturb the participation in the study * Cognitive deficits, which could disturb the participation in the study * Contraindications for rTMS as listed by the Guidelines of the International Federation of Clinical Neurophysiology (Rossi et al. 2009) i.e. seizure in the past, epilepsy, presence of magnetic material in the reach of magnetic field, pregnancy, likelihood to get pregnant, intracranial electrodes, cardiac pacemaker or intracardiac lines, frequent syncopes

Design outcomes

Primary

MeasureTime frameDescription
Numeric Pain Severity Scale after rTMSBefore rTMS, immediately after (on same day) finishing rTMS.Total score 10, with higher scores representing more severe pain. Change from baseline score in the Numeric Pain Severity Scale to the measurement taken after finishing rTMS.
Numeric Pain Severity Scale First Follow UpBefore rTMS, two weeks after finishing rTMSTotal score 10, with higher scores representing more severe pain. Change from baseline score in the Numeric Pain Severity Scale to the measurement taken two weeks after finishing rTMS.
Numeric Pain Severity Scale Second Follow UpBefore rTMS, four weeks after finishing rTMSTotal score 10, with higher scores representing more severe pain. Change from baseline score in the Numeric Pain Severity Scale to the measurement taken four weeks after finishing rTMS.
Visual Analog Scale of Pain SeverityThrough study completion, an average of 10 weeksAn analog scale of the length of 100 milimeter. Total score of 100, with higher scores representing more severe pain. Change through the study.

Secondary

MeasureTime frameDescription
36-Item Short Form Health Survey First Follow UpBefore rTMS, two weeks after finishing rTMSTotal score, range 0 to 800, with lower values representing a worse outcome. Change from baseline score in the 36-Item Short Form Health Survey to the measurement taken two weeks after finishing rTMS.
36-Item Short Form Health Survey Second Follow UpBefore rTMS, four weeks after finishing rTMSTotal score, range 0 to 800, with lower values representing a worse outcome. Change from baseline score in the 36-Item Short Form Health Survey to the measurement taken four weeks after finishing rTMS.
Quality of Life in Neurological Disorders (Neuro-QoL) Upper Extremity Function after rTMSBefore rTMS, immediately after (on same day) finishing rTMS.Total score, range 0 to 100, with lower values representing a worse outcome. Change from baseline score in Neuro-Qol Upper Extremity Function to the measurement taken after finishing rTMS.
Quality of Life in Neurological Disorders (Neuro-QoL) Upper Extremity Function First Follow UpBefore rTMS, two weeks after finishing rTMSTotal score, range 0 to 100, with lower values representing a worse outcome. Change from baseline score in Neuro-Qol Upper Extremity Function to the measurement taken two weeks after finishing rTMS.
Quality of Life in Neurological Disorders (Neuro-QoL) Upper Extremity Function Second Follow UpBefore rTMS, four weeks after finishing rTMSTotal score, range 0 to 100, with lower values representing a worse outcome. Change from baseline score in Neuro-Qol Upper Extremity Function to the measurement taken four weeks after finishing rTMS.
Assessment of pain threshold to electric stimuli after rTMSBefore rTMS, immediately after (on same day) finishing rTMS.Electrocutaneus stimulation with gradually increasing intensity from 0mA until a patient reports that the sensation has become painful. Change from baseline pain threshold to the measurement taken after finishing rTMS.
Assessment of sensory threshold to electric stimuli after rTMSBefore rTMS, immediately after (on same day) finishing rTMS.Electrocutaneus stimulation with gradually increasing intensity from 0mA until a patient reports the first nonpainful tactile sensation. Change from baseline sensory threshold to the measurement taken after finishing rTMS.
Assessment of pain threshold to electric stimuli First Follow UpBefore rTMS, two weeks after finishing rTMSElectrocutaneus stimulation with gradually increasing intensity from 0mA until a patient reports that the sensation has become painful. Change from baseline pain threshold to the measurement taken two weeks after finishing rTMS.
Assessment of sensory threshold to electric stimuli First Follow UpBefore rTMS, two weeks after finishing rTMSElectrocutaneus stimulation with gradually increasing intensity from 0mA until a patient reports the first nonpainful tactile sensation. Change from baseline sensory threshold to the measurement taken two weeks after finishing rTMS.
Assessment of pain threshold to electric stimuli Second Follow UpBefore rTMS, four weeks after finishing rTMSElectrocutaneus stimulation with gradually increasing intensity from 0mA until a patient reports that the sensation has become painful. Change from baseline pain threshold to the measurement taken four weeks after finishing rTMS.
Assessment of sensory threshold to electric stimuli Second Follow UpBefore rTMS, four weeks after finishing rTMSElectrocutaneus stimulation with gradually increasing intensity from 0mA until a patient reports the first nonpainful tactile sensation. Change from baseline sensory threshold to the measurement taken four weeks after finishing rTMS.
Assessment of cold sensation threshold to cold stimuli after rTMSBefore rTMS, immediately after (on same day) finishing rTMS.Stimulation with cold temperature stimuli, gradually colder, starting from from 32 degree Celcius until patient will report that he feels cold. Change from baseline cold sensation threshold to the measurement taken after finishing rTMS.
Assessment of pain threshold to cold temeprature stimuli after rTMSBefore rTMS, immediately after (on same day) finishing rTMS.Stimulation with cold temperature stimuli, gradually colder, starting from 32 degree Celcius until patient starts to perceive stimuli as painful. Change from baseline pain threshold to the measurement taken after finishing rTMS.
Assessment of cold sensation threshold to cold temeprature stimuli First Follow UpBefore rTMS, two weeks after finishing rTMSStimulation with cold temperature stimuli, gradually colder, starting from from 32 degree Celcius until patient will report that he feels cold. Change from baseline cold sensation threshold to the measurement taken two weeks after finishing rTMS.
Hospital Anxiety and Depression Scale after rTMSBefore rTMS, immediately after (on same day) finishing rTMS.Total score 64, with higher scores representing more severe depression. Change from baseline score in the Hospital Anxiety and Depression Scale to the measurement taken after finishing rTMS.
Assessment of cold sensation threshold to cold temeprature stimuli Second Follow UpBefore rTMS, four weeks after finishing rTMSStimulation with cold temperature stimuli, gradually colder, starting from from 32 degree Celcius until patient will report that he feels cold. Change from baseline cold sensation threshold to the measurement taken four weeks after finishing rTMS.
Assessment of pain threshold to cold temeprature stimuli Second Follow UpBefore rTMS, four weeks after finishing rTMSStimulation with cold temperature stimuli, gradually colder, starting from 32 degree Celcius until patient starts to perceive stimuli as painful. Change from baseline pain threshold to the measurement taken four weeks after finishing rTMS.
Assessment of warmth sensation threshold to warm temeprature stimuli after rTMSBefore rTMS, immediately after (on same day) finishing rTMS.Stimulation with warm temperature stimuli, gradually warmer, starting from from 32 degree Celcius until patient will report that he feels warmth. Change from baseline warmth sensation threshold to the measurement taken after finishing rTMS.
Assessment of pain threshold to warm temeprature stimuli after rTMSBefore rTMS, immediately after (on same day) finishing rTMS.Stimulation with warm temperature stimuli, gradually warmer, starting from 32 degree Celcius until patient starts to perceive stimuli as painful. Change from baseline pain threshold to the measurement taken after finishing rTMS.
Assessment of warmth sensation threshold to warm temeprature stimuli First Follow UpBefore rTMS, two weeks after finishing rTMSStimulation with warm temperature stimuli, gradually warmer, starting from from 32 degree Celcius until patient will report that he feels warmth. Change from baseline warmth sensation threshold to the measurement taken two weeks after finishing rTMS.
Assessment of pain threshold to warm temeprature stimuli First Follow UpBefore rTMS, two weeks after finishing rTMSStimulation with warm temperature stimuli, gradually warmer, starting from 32 degree Celcius until patient starts to perceive stimuli as painful. Change from baseline pain threshold to the measurement taken two weeks after finishing rTMS.
Assessment of warmth sensation threshold to warm temeprature stimuli Second Follow UpBefore rTMS, four weeks after finishing rTMSStimulation with warm temperature stimuli, gradually warmer, starting from from 32 degree Celcius until patient will report that he feels warmth. Change from baseline warmth sensation threshold to the measurement taken four weeks after finishing rTMS.
Assessment of pain threshold to warm temeprature stimuli Second Follow UpBefore rTMS, four weeks after finishing rTMSStimulation with warm temperature stimuli, gradually warmer, starting from 32 degree Celcius until patient starts to perceive stimuli as painful. Change from baseline pain threshold to the measurement taken four weeks after finishing rTMS.
Bilateral Dynamometric Assessment of the strength of the index finger flexion after rTMSBefore rTMS, immediately after (on same day) finishing rTMS.Change from baseline strength of the index finger flexion to the measurement taken after finishing rTMS.
Bilateral Dynamometric Assessment of the strength of the foot extension after rTMSBefore rTMS, immediately after (on same day) finishing rTMS.Change from baseline strength of the foot extension to the measurement taken after finishing rTMS.
Bilateral Dynamometric Assessment of the strength of the index finger flexion First Follow UpBefore rTMS, two weeks after finishing rTMSChange from baseline strength of the index finger flexion to the measurement taken two weeks after finishing rTMS.
Bilateral Dynamometric Assessment of the strength of the foot extension flexion First Follow UpBefore rTMS, two weeks after finishing rTMSChange from baseline strength of the foot extension to the measurement taken two weeks after finishing rTMS.
Bilateral Dynamometric Assessment of the strength of the index finger flexion Second Follow UpBefore rTMS, four weeks after finishing rTMSChange from baseline strength of the index finger flexion to the measurement taken four weeks after finishing rTMS.
Bilateral Dynamometric Assessment of the strength of the foot extension Second Follow UpBefore rTMS, four weeks after finishing rTMSChange from baseline strength of the index foot extension to the measurement taken four weeks after finishing rTMS.
Assessment of pain threshold to cold temeprature stimuli First Follow UpBefore rTMS, two weeks after finishing rTMSStimulation with cold temperature stimuli, gradually colder, starting from 32 degree Celcius until patient starts to perceive stimuli as painful. Change from baseline pain threshold to the measurement taken two weeks after finishing rTMS.
Hospital Anxiety and Depression Scale First Follow UpBefore rTMS, two weeks after finishing rTMSTotal score 64, with higher scores representing more severe depression. Change from baseline score in the Hospital Anxiety and Depression Scale to the measurement taken two weeks after finishing rTMS.
Hospital Anxiety and Depression Scale Second Follow UpBefore rTMS, four weeks after finishing rTMSTotal score 64, with higher scores representing more severe depression. Change from baseline score in the Hospital Anxiety and Depression Scale to the measurement taken four weeks after finishing rTMS.
36-Item Short Form Health Survey after rTMSBefore rTMS, immediately after (on same day) finishing rTMS.Total score, range 0 to 800, with lower values representing a worse outcome. Change from baseline score in the 36-Item Short Form Health Survey to the measurement taken after finishing rTMS.

Countries

Poland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026